Literature DB >> 6202446

Plasma forms of somatomedin and the binding protein phenomenon.

R L Hintz.   

Abstract

Somatomedin and peptides are bound tightly to a plasma complex in vivo. There are at least two macromolecular forms of somatomedin complexes: one with a molecular weight of 150 000 the ('150 K' complex) and one of 45 000 (the '45 K' complex). These macromolecular complexes clearly increase the half-life of somatomedins in plasma. The 150 K complex appears to have a three-subunit structure consisting of the somatomedin peptide, a specific Sm/IGF binding protein, and an acid-labile component. In addition to the binding proteins contained in the 150 K and 45 K complexes, plasma also contains unsaturated Sm/IGF binding proteins of approximately 40 000 molecular weight. The somatomedin complex forms not only have longer half-lives, but in this form their biological actions (both insulin-like and growth-promoting) are clearly modified. In addition, it is possible that the complex forms play a role in tissue selectivity and/or delivery of active somatomedin peptide to the intracellular space. An understanding of the somatomedin complexes, plasma complexes and binding proteins is necessary before the physiological roles of the somatomedin peptides can be defined more clearly.

Mesh:

Substances:

Year:  1984        PMID: 6202446     DOI: 10.1016/s0300-595x(84)80007-9

Source DB:  PubMed          Journal:  Clin Endocrinol Metab        ISSN: 0300-595X


  11 in total

Review 1.  Insulin-like growth factors in central nervous system tumors.

Authors:  R P Glick; T Lichtor; T G Unterman
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

2.  Insulin-like growth factor binding proteins from cultured human fibroblasts. Characterization and hormonal regulation.

Authors:  C A Conover; F Liu; D Powell; R G Rosenfeld; R L Hintz
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

3.  Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats.

Authors:  J Zapf; C Hauri; M Waldvogel; E R Froesch
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

4.  Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats.

Authors:  J Zapf; C Hauri; M Waldvogel; E Futo; H Häsler; K Binz; H P Guler; C Schmid; E R Froesch
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

5.  Differential regulation of insulin-like growth factor binding protein secretion from human decidual cells by IGF-I, insulin, and relaxin.

Authors:  K M Thraikill; D R Clemmons; W H Busby; S Handwerger
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  Recognition of insulin-like-growth-factor-binding proteins in serum and amniotic fluid by an antiserum against a low-molecular-mass insulin-like-growth-factor-inhibitor/binding protein.

Authors:  G T Ooi; A C Herington
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

7.  Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism).

Authors:  W H Daughaday; B Trivedi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

8.  Type II insulin-like growth factor receptor is present in rat serum.

Authors:  W Kiess; L A Greenstein; R M White; L Lee; M M Rechler; S P Nissley
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

9.  Regulation of lipoprotein lipase in primary cultures of isolated human adipocytes.

Authors:  P A Kern; S Marshall; R H Eckel
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

10.  Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1).

Authors:  A Brinkman; C Groffen; D J Kortleve; A Geurts van Kessel; S L Drop
Journal:  EMBO J       Date:  1988-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.